Merck & Co.’s Keytruda Stakes Another Adjuvant Flag, In RCC

 
• By Joseph Haas
Kidney cancer
Merck & Co. hopes to add adjuvant RCC to Keytruda's label

More from Clinical Trials

More from R&D